Simvastatin attenuates ventilator-induced lung injury in mice by Müller, Holger C et al.
RESEARCH Open Access
Simvastatin attenuates ventilator-induced lung
injury in mice
Holger C Müller
1*, Katharina Hellwig
1, Simone Rosseau
1, Thomas Tschernig
2, Andreas Schmiedl
3, Birgitt Gutbier
1,
Bernd Schmeck
1,4, Stefan Hippenstiel
1, Harm Peters
5, Lars Morawietz
6, Norbert Suttorp
1, Martin Witzenrath
1
Abstract
Introduction: Mechanical ventilation (MV) is a life saving intervention in acute respiratory failure without
alternative. However, particularly in pre-injured lungs, even protective ventilation strategies may evoke ventilator-
induced lung injury (VILI), which is characterized by pulmonary inflammation and vascular leakage. Adjuvant
pharmacologic strategies in addition to lung protective ventilation to attenuate VILI are lacking. Simvastatin
exhibited anti-inflammatory and endothelial barrier stabilizing properties in vitro and in vivo.
Methods: Mice were ventilated (12 ml/kg; six hours) and subjected to simvastatin (20 mg/kg) or sham treatment.
Pulmonary microvascular leakage, oxygenation, pulmonary and systemic neutrophil and monocyte counts and
cytokine release in lung and blood plasma were assessed. Further, lung tissue was analyzed by electron
microscopy.
Results: Mechanical ventilation induced VILI, displayed by increased pulmonary microvascular leakage and
endothelial injury, pulmonary recruitment of neutrophils and Gr-1
high monocytes, and by liberation of inflammatory
cytokines in the lungs. Further, VILI associated systemic inflammation characterized by blood leukocytosis and
elevated plasma cytokines was observed. Simvastatin treatment limited pulmonary endothelial injury, attenuated
pulmonary hyperpermeability, prevented the recruitment of leukocytes to the lung, reduced pulmonary cytokine
levels and improved oxygenation in mechanically ventilated mice.
Conclusions: High-dose simvastatin attenuated VILI in mice by reducing MV-induced pulmonary inflammation and
hyperpermeability.
Introduction
In acute respiratory failure, mechanical ventilation (MV)
is a life saving treatment without alternatives, and MV
is also employed following surgery or trauma. One third
of all patients in intensive care units worldwide receive
MV [1]. However, particularly in preinjured lungs even
minimal MV-associated physical stress may evoke venti-
lator-induced lung injury (VILI), an important undesir-
able effect of respirator therapy [2,3]. VILI is
characterized by a pulmonary inflammatory response
with the liberation of cytokines, recruitment of leuko-
cytes to the lung and increased lung permeability, con-
secutively resulting in lung edema, surfactant
dysfunction, impaired lung compliance and deterioration
of pulmonary gas exchange [4]. Clinical studies of
Amato et al. and the ARDS Network revealed that mini-
mization of MV-induced physical stress by reduction of
tidal volumes to 6 ml/kg significantly improved the clin-
ical outcome of mechanically ventilated patients [5,6].
However, even low tidal volume ventilation of healthy
lungs causes lung injury [7], and particularly preinjured
lungs are sensitive to the development of VILI even in
the setting of lung-protective ventilation [2,3]. As the
necessity to guarantee sufficient gas exchange limits a
further substantial reduction of tidal volumes, new adju-
vant pharmacological therapies in addition to lung-pro-
tective ventilation are needed to prevent VILI.
Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor belonging to the group
of statins may be a promising drug candidate for adju-
vant pharmacotherapy in MV. Besides well-known lipid
lowering properties, simvastatin exhibits pleiotropic
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any medium, provided the original work is properly cited.effects that attenuated acute lung injury (ALI), including
reduction of pulmonary microvascular leakage, limita-
tion of pulmonary leukocyte infiltration, and attenuation
of pulmonary and systemic hyperinflammation in differ-
ent experimental settings [8-11]. Moreover, statins may
alter inflammatory responses in humans. Healthy volun-
teers subjected to lipopolysacharide (LPS) inhalation
developed lung inflammation, which was attenuated by
simvastatin treatment [12]. Further, statin treatment was
associated with improved survival in sepsis and severe
community acquired pneumonia [13-16].
Pulmonary and systemic hyperinflammation, leukocyte
recruitment to the lungs, and the development of pul-
monary microvascular leakage are crucial components
of VILI [4,17]. We thus hypothesized that simvastatin
m a yr e d u c eV I L Ia n dm a yb eap r o m i s i n ga d j u v a n t
pharmacologic strategy to limit VILI in addition to lung
protective ventilation.
In the current study, anesthetized mice were subjected
to mechanical ventilation for six hours. Simvastatin
treatment markedly attenuated ventilator-induced pul-
monary microvascular permeability and endothelial
injury, recruitment of neutrophils and Gr-1
high mono-
cytes, as well as proinflammatory cytokine levels in the
lung, and improved oxygenation considerably.
Materials and methods
Mice
Female C57BL/6 mice (11 to 15 weeks, 20 to 22 g)
(Charles River, Sulzfeld, Germany) were employed. Pro-
cedures were approved by institutional and governmen-
tal authorities.
Mechanical ventilation
Mice were anesthetized by intraperitoneal injections of
Fentanyl (0.075 mg/kg), Midazolam (1.5 mg/kg) and
Medetomedin (0.75 mg/kg). Repetitive applications of
Fentanyl (0.016 mg/kg), Midazolam (0.33 mg/kg) and
Medetomedin (0.16 mg/kg) were done via an intraperi-
toneal catheter when required to guarantee adequate
anaesthesia over the whole experiment. Body-tempera-
ture was maintained at 37°C by a heating pad. After tra-
cheotomy and intubation, mice were ventilated
(MiniVent, Hugo-Sachs-Electronics, March-Hugstetten,
Germany) with 50% oxygen; tidal volume (VT)7m l / k g ;
respiratory rate (RR) 240 minute
-1; positive end-expira-
tory pressure (PEEP) 6 cmH2O. A carotid artery catheter
was placed for blood pressure monitoring and infusion
of NaCl 0.9% containing 100 mmol/l HCO3
- (350 μl/h).
There was no additional fluid support in any conducted
experiment. A urinary catheter was inserted. VT, RR, air-
way pressure, peripheral oxygen saturation and urine
output were monitored (Pulmodyn, Hugo-Sachs-Electro-
nics, March-Hugstetten, Germany; MouseOx, STARR
Life-Sciences, Oakmont, PA, USA). After preparation, a
recruitment maneuver was performed (airway pressure
35 cmH2O for 5 sec) before respirator settings were
adjusted for 6 h to VT 12 ml/kg, RR 120 minute
-1, PEEP
2c m H 2O. All mice survived the protocol. At termina-
tion of the experiments mice were sacrificed by exsan-
guination via the carotid catheter. Non-ventilated mice
served as controls.
Simvastatin treatment
Simvastatin (Sigma, Steinheim, Germany) was dissolved
in ethanol and diluted with saline. Mice received i.p.
injections of 20 mg/kg simvastatin or solvent 24 h and
1 h before the VILI experiment. Non-ventilated mice
were treated in according intervals. Simvastatin treat-
ment had no impact on overall cholesterol, HDL and
LDL cholesterol in studied mice.
Blood gas analyses
Blood samples were analyzed for paO2,p aCO2,p h ,
HCO3
-,S B E ,L a c t a t e ,N a
+,K
+,C l
-,C a
2+ by blood gas
analyzer (ABL-800, Radiometer, Copenhagen, Denmark).
P/F ratio was calculated as paO2 /FiO2.
Lung permeability
Human-Serum-Albumin (HSA; 1 mg) was injected via
carotid artery catheter or tail vein in ventilated or non-
ventilated mice, respectively, 90 minutes before the
experiment termination. Mice were sacrificed and
bronchoalveolar lavage (BAL) of the right lung was per-
formed with 2 × 400 μl saline. BAL- and plasma HSA-
levels were quantified by ELISA (enzyme-linked immuno
sorbent assay) (Bethyl (biomol), Hamburg, Germany).
Permeability was assessed by calculating the HSA BAL/
plasma ratio.
Electron microscopy
Lungs were flushed via the pulmonary artery, cut,
immersion-fixed (1.5% glutaraldehyde, 1.5% paraformal-
dehyde in 0.15 M HEPES), rinsed (0.1 mmol/l HEPES,
0.1 mmol/l cacodylate buffer) and osmicated (1%
osmium tetroxide in 0.1 mmol/l cacodylate buffer).
After rinsing in 0.1 mmol/l cacodylate buffer and dis-
tilled water, specimens were stained in half-saturated
aqueous uranylacetate solution (1:1). Samples were
dehydrated in ascending acetone concentrations,
embedded in epon, cut (70 nm), stained with lead citrate
and uranyl-acetate, and analyzed.
Differential cell count lung
Lungs were flushed. The left lung was digested in RPMI
containing Collagenase and DNAse for 1 h. Leukocytes
were extracted by meshing the lung tissue through a cell
strainer (100 μm) and counted by haemocytometer and
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scatter/forward-scatter properties and CD45, Gr-1 and
F4-80 expression.
Differential cell count blood
Leukocytes were quantified by flowcytometry using Tru-
Count-Tubes and differentiated according to their side-
scatter/forward-scatter properties and CD45 and Gr-1
expression.
Quantification of cytokines
Cytokines were quantified from total protein of flushed
homogenized left lungs and blood samples (BioRad,
Hercules, CA, USA).
Measurement of Alanine transaminase levels
Alanine transaminase (ALT) levels were measured by
routine laboratory test at the Institute of Laboratory
Medicine and Pathobiochemistry of the Charité -
Universitätsmedizin Berlin.
Statistic analyses
Groups were compared using One-Way-ANOVA fol-
lowing Newman-Keuls post test. For comparison of two
groups Mann-Whitney U-Test was applied. P-values <
0.05 were considered significant. Data are represented as
mean +/- SEM.
Results
Simvastatin prevented oxygenation failure in VILI
The decline of the peripheral oxygen saturation (SpO2)
observed in ventilated mice was prevented by Simvasta-
tin treatment (Figure 1a). At the termination of the
experiment, blood gas analysis was performed in arterial
blood samples. The P/F ratio was higher in simvastatin
treated mice (Figure 1b).
Simvastatin reduced VILI-associated pulmonary vascular
leakage
MV induced a marked increase of pulmonary microvas-
cular permeability in mice, indicated by an elevated
HSA BAL/plasma ratio. Pulmonary hyperpermeability
was decreased by Simvastatin treatment (Figure 2).
Simvastatin attenuated endothelial injury in ventilated
mice
Non-ventilated, untreated or simvastatin treated mice
exhibited intact alveolar epithelium and capillary
endothelium (Figure 3a-d). Capillary endothelial cells of
ventilated and untreated mice were swollen and showed
loss of intracellular vesicles and caveolae (Figure 3e, f).
In ventilated and simvastatin treated lungs, endothelial
cells displayed fewer signs of injury as compared to
ventilated and untreated mice. Swelling of endothelial
cells occurred only sporadically, and normal distribution
of vesicles and caveolae was preserved by simvastatin
(Figure 3g, h).
Simvastatin limited the recruitment of PMN and Gr-1
high
monocytes to the lung in VILI
MV evoked PMN and Gr-1
high monocyte recruitment to
the lung, which was reduced by simvastatin treatment
(Figure 4a, b). Further, MV elicited an increase of circu-
lating PMN and monocyte counts, whereas lymphocyte
counts were unaltered in the blood (Figure 4c-f). Notably,
following simvastatin treatment monocyte counts were
increased significantly and PMN counts were increased
by trend in blood of ventilated mice (Figure 4c, d).
Simvastatin treatment attenuated VILI-associated
pulmonary cytokine production
MV induced an increase of IL-1b, IL-6, IL-12p40, MIP-
1a, MIP-2 and MCP-1 in the lung tissue. Simvastatin
Figure 1 Simvastatin improved oxygenation in VILI. (a)
Peripheral Oxygen Saturation (SpO2) was monitored continuously
and (b) P/F ratio was assessed at the end of the 6 h ventilation
period in simvastatin (6 h Vent. + Simva) or sham (6 h Vent.) treated
mice. Simvastatin treatment prevented the decline of SpO2 and
improved oxygenation in VILI. (a: 6 h Vent. N = 8; 6 h Vent. + Simva
n = 10; b: 6 h Vent. N = 7; 6 h Vent. + Simva n =9 ;* P < 0.05).
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of IL-1b, IL-12p40 and MIP-1a in the lung tissue
(Figure 5).
Simvastatin treatment attenuated VILI-associated
IL-12p40 increase in plasma
MV evoked an increase of IL-1b, IL-6, IL-12p40, MIP-
1a, MIP-2 and MCP-1 in blood plasma. Simvastatin
treatment attenuated the VILI-associated increase of IL-
12p40 in the plasma. All other quantified cytokines did
not show statistically significant alterations due to sim-
vastatin treatment in ventilated mice (Table 1).
Hemodynamics, urine output electrolytes, acid-base
homeostasis and markers of hepatic and renal function
Continuous monitoring of systemic arterial blood pres-
sure and quantification of electrolytes, parameters of
acid-base homeostasis, renal and global hepatic function
and urine output at the end of the experiment demon-
strated standardization of experimental procedures.
Simvastatin treatment did not alter blood pressure,
urine output electrolyte levels or acid-base homeostasis
in mechanically ventilated mice. Further simvastatin had
no impact on renal function or ALT levels in plasma
(Table 2).
Discussion
Mechanical ventilation may evoke ventilator-induced
lung injury even under employment of protective ven-
tilation strategies. Adjuvant pharmacologic approaches
to reduce VILI in addition to protective ventilation
may further improve morbidity and mortality of venti-
lated patients. Investigating VILI in a mouse model of
M V ,t h ec u r r e n ts t u d yf o rt h ef i r s tt i m ep r o v i d e s
experimental evidence that simvastatin treatment may
limit VILI in vivo. Simvastatin reduced VILI-associated
hyperpermeability, endothelial injury, neutrophil and
monocyte recruitment, and inflammation in murine
lungs.
Mouse models have been successfully used to investi-
gate pathomechanisms of VILI [18-20]. The currently
employed mouse model allowed us to analyze key fea-
tures of VILI while avoiding detrimental lung injury due
to high airway pressures, tidal volumes or respiration
rates. Although a VT of 6 ml/kg is recommended for
lung protective ventilation, we employed a VT of 12 ml/
kg which allowed for limitation of respiratory rates in
our model, an important independent trigger of VILI in
mice [21]. Further lung stress and lung strain, generated
b yaV T of 12 ml/kg affecting healthy lungs in the cur-
rent model may apply in ventilated areas of inhomogen-
eously injured lungs even under lung protective
ventilation according to the baby lung concept of the
inhomogeneous ARDS lung [22,23]. To further enhance
clinical relevance, we prevented hemodynamic instability
by fluid support and metabolic acidosis by adequate
infusion of sodium bicarbonate. In summary, a mouse
model was established for the current study, which
evoked moderate lung injury by ventilation for a six-
hour period.
Microvascular leakage, a hallmark of VILI evokes lung
edema, reduction of lung compliance, surfactant dys-
function, and finally deterioration of pulmonary gas
exchange [4]. Statins prevented pulmonary hyperperme-
ability in ALI evoked by different stimuli, including
endotoxin and ischemia/reperfusion [8-10]. Of note,
simvastatin treatment also reduced VILI-associated pul-
monary hyperpermeability and improved pulmonary gas
exchange in the current study.
Different mechanisms of endothelial barrier protection
by HMG-CoA reductase inhibitors have been reported,
including inhibition of the RhoA/Rho kinase pathway
with consecutive reduction of endothelial myosin light
chain phosphorylation [24-26], stabilization of endothe-
lial junctions by polymerization of cortical actin [25], as
well as downregulation of endothelial caldesmon and
upregulation of integrin b4 expression in endothelial
cells [25]. Although these mechanisms were not evalu-
ated in detail in the current study, they may have been
contributing to the observed improvement of barrier
function in murine VILI. Notably, an additional way of
endothelial cell protection by simvastatin has now been
observed by electron microscopy. Simvastatin attenuated
VILI-evoked cell swelling and loss of intracellular vesicle
Figure 2 Simvastatin reduced VILI-associated lung
hyperpermeability. Human serum albumin (HSA; 1 mg) was
injected 90 minutes prior to termination of the experiment. In non-
ventilated simvastatin (NV + Simva) or sham (NV) treated mice, and
in ventilated and simvastatin (6 h Vent. + Simva) or sham (6 h Vent.)
treated mice, HSA levels in plasma and BAL were determined.
Simvastatin treatment reduced VILI associated lung
hyperpermeability. (NV n = 6; NV + Simva n = 7; 6 h Vent. N =7 ;6
h Vent. + Simva n =6 ;* P < 0.05, ***P < 0.001).
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energy depletion and impaired cell metabolism. Previous
in vitro and in vivo studies linked cyclic stretch with
apoptosis and necrosis of pulmonary epithelial cells
[27,28]. In line with the works of Vaneker et al. this
study provides ultrastructural in vivo evidence for lung
endothelial cell injury following ventilation with
moderate tidal volumes [29]. The observed morphologic
findings resemble alterations observed in capillary stress
failure previously described by West et al. To the best
of our knowledge this is the first study showing that a
pharmacologic treatment attenuated endothelial injury
VILI. This previously undescribed effect of simvastatin
treatment suggests a so far unknown beneficial effect of
Figure 3 Simvastatin reduced VILI-associated endothelial injury. In lung sections of non ventilated, sham treated mice (NV) (a, b) and non-
ventilated, simvastatin treated mice (NV + Simva) (c, d), structurally intact capillaries containing numerous caveolae and vesicles in endothelial
cells were seen. In lung sections of ventilated, sham treated mice (6 h Vent.) (e, f), capillaries showed pronounced endothelial cell swelling as
well as loss of intracellular vesicles and caveolae. Lungs of ventilated, simvastatin treated mice (6 h Vent. + Simva) (g, h) had intact capillaries,
and neither signs of endothelial cell swelling, nor reduction of intracellular vesicles was observed. (Representative images out of n = 8 each
group are shown. Bar 2 μm).
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examined in future studies.
In VILI, PMN and Gr-1
high monocytes infiltrate the
lungs and have been identified as major effector cells for
the development of tissue damage [30-32]. Reportedly,
simvastatin inhibited tissue leukocyte infiltration in ALI
both in animal experiments and in humans [8,9,12].
Leukocyte rolling, adhesion and transmigration were
attenuated by simvastatin, at least partly by reduction of
adhesion molecules including CEACAM-1, VCAM-1
Figure 4 Simvastatin treatment limited VILI-associated pulmonary leukocyte infiltration. After 6 h mechanical ventilation (MV) of
simvastatin (6 h Vent + Simva) or sham treated mice (6 h Vent.) and in non-ventilated sham (NV) or simvastatin (NV + Simva) treated mice,
leukocytes isolated from whole left lung tissue and from blood were differentiated by flow cytometry. MV increased pulmonary PMN (a) and GR-
1
high monocytes (b). Simvastatin reduced PMN and monocyte counts in the lungs of ventilated mice. MV also increased circulating blood
neutrophils (c) and Gr-1
high monocytes (d), whereas leukocyte (e) and lymphocyte (f) counts were not significantly altered by MV (F). PMN and
Gr-1
high monocyte counts were higher in Simvastatin treated, ventilated mice (6 h Vent. + Simva), as compared to sham treated, ventilated mice
(6 h Vent.). (a-b: NV n = 6; NV + Simva n = 7; 6 h Vent. N = 7; 6 h Vent. + Simva n = 6. c-d: NV n = 9; NV + Simva n = 9; 6 h Vent. N =8 ;6h
Vent. + Simva n =8 ;* P < 0.05; **P < 0.01, ***P < 0.001).
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of PMN and Gr-1
high monocytes in murine VILI was
diminished by simvastatin in the current study. More-
over, an MV-induced increase of circulating PMN and
Gr-1
high monocytes in the blood was even more pro-
nounced in simvastatin-treated mice. This observation
may suggest that simvastatin-evoked inhibition of
endothelial leukocyte recruitment contributed to
reduced pulmonary and concomitantly increased blood
counts of PMN and Gr-1
high monocytes.
Simvastatin reduced production and liberation of var-
i o u sc y t o k i n e si na n i m a lm o d e l so fA L I ,s e p s i sa n d
asthma as well as in humans following LPS-inhalation
[9,11,12,37-40]. In the current study, VILI-associated
pulmonary production of IL-1b,M I P - 1 a and IL-12p40
was reduced by simvastatin treatment. Thus, alteration
Figure 5 Simvastatin attenuated VILI-associated pulmonary cytokine production. Simvastatin (6 h Vent. + Simva) or sham treated mice
(6 h Vent.) subjected to 6 h of mechanical ventilation, and non-ventilated sham (NV) or simvastatin (NV + Simva) treated mice were sacrificed.
Cytokine levels in homogenized lung tissue were quantified. MV evoked an increase of pulmonary cytokines. Simvastatin treatment limited VILI
associated production of IL-1b, MIP-1a and IL-12p40. (n = 8 each group; *P < 0.05, **P < 0.01, ***P < 0.001). (b.t., below threshold).
Table 1 Simvastatin treatment reduced IL-12p40 levels in plasma
NV NV + Simva 6 h Vent. 6 h Vent. + Simva
mean (pg/μl) SD mean (pg/μl) SD mean (pg/μl) SD mean (pg/μl) SD
IL-1b 445.30 100.70 505.30 52.19 763.2 *** 95.38 738.8 ### 100.40
IL-6 57.58 62.99 133.40 90.38 915.3 *** 459.00 993.9 ### 364.60
IL-12p40 462.10 99.32 593.10 128.60 2,352 *** 783.40 1,785 ###,
a 372.50
MIP-1a 307.20 149.10 386.50 78.94 918.6 *** 318.60 900.8 ### 128.20
MIP-2 15.28 35.02 10.03 9.42 95.32 ** 49.21 67.25 # 23.73
MCP-1 99.84 17.33 153.50 29.41 758.9 * 404.90 559.70 133.30
Cytokine levels were assessed in blood plasma after 6 h mechanical ventilation (MV) of simvastatin (6 h Vent + Simva) or sham treated mice (6 h Vent.) and in
plasma of non-ventilated simvastatin (NV + Simva) or sham (NV) treated mice. MV induced a systemic inflammatory response indicated by elevated cytokine
levels in blood. Simvastatin treatment reduced IL-12p40 levels in plasma significantly. The levels of IL-1b, MIP-1a, IL-6, MIP-2 and MCP-1 in VILI did not show
statistically significant alterations due to simvastatin treatment. (n = 8 each group; * P < 0.05, ** P < 0.01, *** P < 0.001 vs. NV; # P < 0.05, ### P < 0.001 vs.
NV + Simva;
a P < 0.05 vs. 6 h Vent.).
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tion of PMN and Gr-1
high monocyte influx into the
l u n g si nt h i ss t u d y .P a r t i c u l a r l yI L - 1 b m a yb eak e y
mediator in VILI, as IL-1b blockade as well as IL-1b
deficiency resulted in reduced pulmonary PMN recruit-
ment and hyperpermeability in animal models of VILI
[41]. Therefore, dampening of pulmonary IL-1b produc-
tion by simvastatin may have been adding to the
observed attenuation of microvascular leakage, pulmon-
ary leukocyte recruitment and endothelial cell injury.
Although increasing evidence derived from experi-
mental and observational studies suggests beneficial
effects of simvastatin in ALI as well as in pneumonia
[8-11,14,16,42], a retrospective study analyzing an ALI
patient cohort did not find an outcome improvement by
conventional statin treatment [43]. Of note, statin doses
of 5 mg/kg/d did not improve experimental ALI [8],
whereas higher doses of 10 to 20 mg/kg/d evoked pro-
tective effects. Further, previous studies suggested a
delay of at least 6 h for the development of barrier-pro-
tective effects by simvastatin [24,25]. Thus, mice were
pretreated with 20 mg/kg/d simvastatin commencing
24 h before the onset of ventilation in the current study.
Although mandatory for this experimental approach,
simvastatin pre-treatment does not match the clinical
scenario. However, animal studies are limited to hours
while ARDS patients often are ventilated for days or
even weeks. Taking this long time course in account we
believe that simvastatin may deliver its beneficial effects
over time when it is given with the initation of MV.
Notably, an upcoming randomized controlled NHLBI
sponsored trial is going to investigate statin therapy in
ALI (NCT00979121). As patients included in this trial
will presumably receive respirator therapy, the effects of
statins on VILI observed in the current experimental
study may possibly contribute to the outcome of the
treatment arm.
Conclusions
This study shows, for the first time, that high-dose sim-
vastatin markedly reduced VILI-associated microvascular
leakage and improved pulmonary gas exchange in
mechanically ventilated mice. Simvastatin prevented
recruitment of PMN and Gr-1
high monocytes to the
lung, limited pulmonary cytokine production and atte-
nuated endothelial injury in VILI. The data suggest that
high-dose simvastatin offers a promising perspective to
prevent VILI in addition to lung protective ventilation.
Key messages
￿ Simvastatin improved microvascular leakage and
improved oxygenation in VILI.
￿ Simvastatin limited pulmonary hyperinflammation in
VILI.
￿ Simvastatin protected against VILI induced pulmonary
endothelial injury.
￿ Simvastatin offers a promising perspective to limit
VILI in addition to lung protective ventilation.
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